![](/images/graphics-bg.png)
Flaxseed Lignan Complex Administration in Older Human Type 2 Diabetics Manages Central Obesity and Prothrombosis—An Invitation to Further Investigation into Polypharmacy Reduction
Joint Authors
Griscti, O.
Mizier-Barre, K. A.
Muthuthevar, D.
Hobson, J.
Barre, D. E.
Stelmach, E.
Rudiuk, A.
Source
Journal of Nutrition and Metabolism
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-10-04
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
Aim.
Animal and human study evidence supports the hypothesis that flaxseed lignan complex (FLC) at a dose of 600 mg secoisolariciresinol diglucoside (SDG)/day for three months would combat hyperglycaemia, dyslipidemia, blood pressure, central obesity, prothrombotic state, inflammation, and low density lipoprotein (LDL) oxidation.
Methods.
Sixteen type 2 diabetic patients completed this double-blind, randomised crossover placebo-controlled study.
A univariate repeated measures analysis of covariance (significance P<0.05) was followed by a mixed linear model effects analysis corrected for multiple comparisons (MCC).
Results.
Prior to MCC, FLC caused decreased fasting plasma glucose, A1c, inflammation (c-reactive protein (CRP) and interleukin-6 (IL-6)), and increased bleeding time.
After correction for multiple comparisons, FLC induced a statistically significant increase in bleeding time and smaller waist circumference gain.
No treatment effect occurred in the other variables before or after adjustment.
Conclusions.
It is concluded that FLC significantly increased bleeding time thus reducing the prothrombotic state, reduced central obesity gain as measured by waist circumference, and did not affect significantly the other dependent variables measured after adjustment for multiple comparisons.
These findings, not yet published in human type 2 diabetes, suggest that this FLC dose over at least three months, may, subject to further investigation, reduce polypharmacy.
American Psychological Association (APA)
Barre, D. E.& Mizier-Barre, K. A.& Stelmach, E.& Hobson, J.& Griscti, O.& Rudiuk, A.…[et al.]. 2012. Flaxseed Lignan Complex Administration in Older Human Type 2 Diabetics Manages Central Obesity and Prothrombosis—An Invitation to Further Investigation into Polypharmacy Reduction. Journal of Nutrition and Metabolism،Vol. 2012, no. 2012, pp.1-7.
https://search.emarefa.net/detail/BIM-482837
Modern Language Association (MLA)
Barre, D. E.…[et al.]. Flaxseed Lignan Complex Administration in Older Human Type 2 Diabetics Manages Central Obesity and Prothrombosis—An Invitation to Further Investigation into Polypharmacy Reduction. Journal of Nutrition and Metabolism No. 2012 (2012), pp.1-7.
https://search.emarefa.net/detail/BIM-482837
American Medical Association (AMA)
Barre, D. E.& Mizier-Barre, K. A.& Stelmach, E.& Hobson, J.& Griscti, O.& Rudiuk, A.…[et al.]. Flaxseed Lignan Complex Administration in Older Human Type 2 Diabetics Manages Central Obesity and Prothrombosis—An Invitation to Further Investigation into Polypharmacy Reduction. Journal of Nutrition and Metabolism. 2012. Vol. 2012, no. 2012, pp.1-7.
https://search.emarefa.net/detail/BIM-482837
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-482837